Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) saw a large decrease in short interest in the month of August. As of August 31st, there was short interest totalling 455,743 shares, a decrease of 14.7% from the August 15th total of 534,083 shares. Based on an average trading volume of 229,235 shares, the days-to-cover ratio is presently 2.0 days. Currently, 1.0% of the shares of the company are sold short.
In related news, Director Stewart Appelrouth bought 126,000 shares of the business’s stock in a transaction on Tuesday, July 24th. The stock was acquired at an average price of $0.31 per share, for a total transaction of $39,060.00. Following the purchase, the director now directly owns 241,750 shares in the company, valued at $74,942.50. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Thomas K. Equels bought 112,904 shares of the business’s stock in a transaction on Monday, July 23rd. The stock was bought at an average price of $0.31 per share, with a total value of $35,000.24. Following the purchase, the insider now owns 637,823 shares in the company, valued at $197,725.13. The disclosure for this purchase can be found here. Insiders have bought a total of 305,646 shares of company stock valued at $94,061 in the last quarter.
Shares of HEB remained flat at $$0.23 during trading hours on Friday. The stock had a trading volume of 92,432 shares, compared to its average volume of 520,113. Hemispherx BioPharma has a 12-month low of $0.15 and a 12-month high of $0.65.
Hemispherx BioPharma (NYSEAMERICAN:HEB) last issued its quarterly earnings results on Wednesday, August 15th. The specialty pharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter. The business had revenue of $0.03 million for the quarter. Hemispherx BioPharma had a negative net margin of 1,391.11% and a negative return on equity of 49.30%.
About Hemispherx BioPharma
Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).
Featured Story: Understanding Average Daily Trade Volume
Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.